Neoadjuvant IBI308 Bevacizumab Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC

  • STATUS
    Recruiting
  • End date
    Mar 1, 2024
  • participants needed
    36
  • sponsor
    Sun Yat-sen University
Updated on 22 January 2021

Summary

The purpose of this study is to studying neoadjuvant IBI308, bevacizumab, plus pemetrexed and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III non-small cell lung cancer.

Description

Concurrent chemoradiotherapy is the recommended therapeutic approach for patients with unresectable stage III non-small cell lung cancer (NSCLC), although surgery offers the chance of cure. With combined-modality therapy with radiation therapy and chemotherapy, the prognosis of stage III NSCLC remains poor. IBI308 (sintilimab) is a recombinant humanized anti-PD-1 monoclonal antibody. This study is to studying neoadjuvant IBI308, bevacizumab, plus pemetrexed and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III non-small cell lung cancer.

Details
Condition Lung Cancer Stage III
Treatment carboplatin, bevacizumab, Pemetrexed, Thoracic Surgery, IBI308
Clinical Study IdentifierNCT03872661
SponsorSun Yat-sen University
Last Modified on22 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Target population is unresectable stage III non-small cell lung cancer
Written informed consent provided
Subjects should not have a previously detected sensitizing EGFR mutation or ALK fusion oncogene
Male and female patients aged 18 years, < 75 years
Able to comply with the required protocol and follow-up procedures, and able to receive oral medications
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Life expectancy 12 weeks
Adequate hematological function: Absolute neutrophil count (ANC) 2.0 x 109/L, and Platelet count 100 x 109/L, and Hemoglobin 9 g/dL (may be transfused to maintain or exceed this level)
Adequate liver function: Total bilirubin 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) 2.5 x ULN in subjects without liver metastases; 5 x ULN in subjects with liver metastases
Adequate renal function: Serum creatinine 1.25 x ULN, or 60 ml/min
Female subjects should not be pregnant or breast-feeding

Exclusion Criteria

Known severe hypersensitivity to IBI308 or any of the excipients of this product
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody (including any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior chemotherapy or radiotherapy
Subjects with active, known or suspected autoimmune disease. Subjects in conditions not expected to recur in the absence of an external trigger, or not requiring systemic treatment are permitted to enroll
Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Inability to comply with protocol or study procedures
A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study
A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease
History of another malignancy in the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted
Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease)
Patient who has active serious infection (e.g. pyrexia of or 38.0 over)
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
Known history of active Hepatitis B or C
Women who are pregnant or nursing
Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug or puts the subject at high risk for treatment-related complications
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note